Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07192471 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Kyowa Kirin.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07192471 is a Phase 1 study that has not yet begun recruiting, run by Kyowa Kirin. The registered enrollment target is 72 participants.
The verdict
NCT07192471, a Phase 1 study, has not yet begun recruiting, sponsored by Kyowa Kirin.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Interventions
- DRUG KK2223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07192471
The ClinicalTrials.gov registry entry for NCT07192471 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KK2223 is the first listed.
NCT07192471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07192471 about?
NCT07192471 is a clinical study titled "A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma". The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
What is the current status of trial NCT07192471?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-08. Estimated completion is 2030-09.
What interventions are being tested in trial NCT07192471?
The interventions under investigation include: KK2223 (DRUG).
Who is sponsoring clinical trial NCT07192471?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.